Responses
Clinical/translational cancer immunotherapy
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study
Compose a Response to This Article
Other responses
No responses have been published for this article.